Vanguard Group’s Ocera Therapeutics, Inc. OCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-713,169
| Closed | -$813K | – | 4103 |
|
|
2017
Q3 | $813K | Sell |
713,169
-37,773
| -5% | -$40.5K | ﹤0.01% | 3641 |
|
|
2017
Q2 | $871K | Sell |
750,942
-328,808
| -30% | -$382K | ﹤0.01% | 3600 |
|
|
2017
Q1 | $1.42M | Buy |
1,079,750
+905,957
| +521% | +$1.15M | ﹤0.01% | 3485 |
|
|
2016
Q4 | $365K | Sell |
173,793
-256,831
| -60% | -$599K | ﹤0.01% | 3791 |
|
|
2016
Q3 | $1.14M | Buy |
430,624
+21,789
| +5% | +$54.4K | ﹤0.01% | 3542 |
|
|
2016
Q2 | $777K | Buy |
408,835
+4,900
| +1% | +$12.9K | ﹤0.01% | 3676 |
|
|
2016
Q1 | $1.19M | Buy |
403,935
+22,710
| +6% | +$64.8K | ﹤0.01% | 3549 |
|
|
2015
Q4 | $1.19M | Buy |
381,225
+12,903
| +4% | +$44.1K | ﹤0.01% | 3568 |
|
|
2015
Q3 | $1.16M | Buy |
368,322
+11,069
| +3% | +$42.6K | ﹤0.01% | 3585 |
|
|
2015
Q2 | $1.36M | Buy |
357,253
+12,960
| +4% | +$49.7K | ﹤0.01% | 3568 |
|
|
2015
Q1 | $1.62M | Buy |
344,293
+54,809
| +19% | +$316K | ﹤0.01% | 3476 |
|
|
2014
Q4 | $1.84M | Sell |
289,484
-3,352
| -1% | -$19.6K | ﹤0.01% | 3316 |
|
|
2014
Q3 | $1.44M | Buy |
292,836
+85,525
| +41% | +$494K | ﹤0.01% | 3396 |
|
|
2014
Q2 | $1.58M | Buy |
207,311
+400
| +0.2% | +$3.19K | ﹤0.01% | 3352 |
|
|
2014
Q1 | $2.18M | Buy |
206,911
+49,818
| +32% | +$712K | ﹤0.01% | 3183 |
|
|
2013
Q4 | $2.04M | Buy |
157,093
+44,818
| +40% | +$419K | ﹤0.01% | 3175 |
|
|
2013
Q3 | $951K | Buy |
112,275
+103,942
| +1,247% | +$838K | ﹤0.01% | 3382 |
|
|
2013
Q2 | $47K | Buy |
+8,333
| New | +$51.8K | ﹤0.01% | 3767 |
|
Vanguard Group's OCRX Position: Q4 2017 in Review
Vanguard Group sold out of Ocera Therapeutics, Inc. (OCRX) in Q4 2017, closing a stake of 713,169 shares — an estimated $813K sold.
Vanguard Group first reported a position in OCRX in Q2 2013 and held it in 18 quarters. The position peaked at $2.18M in Q1 2014. 0 funds tracked by Wall St. Rank hold OCRX as of Q4 2017.
- Vanguard Group reported no remaining Ocera Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
- Vanguard Group sold 713,169 Ocera Therapeutics, Inc. shares in Q4 2017, an estimated $813K.
- Vanguard Group first reported a position in Ocera Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
- Vanguard Group's Ocera Therapeutics, Inc. position peaked at $2.18M in Q1 2014.
- 0 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q4 2017.
Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.